Auspex Pharmaceuticals is a privately held biopharmaceutical company located in La Jolla, California. The company is a pioneer in the use of deuterium in medicinal chemistry, and is focused on the treatment of hyperkinetic movement disorders including Huntington's disease, Tourette syndrome and tardive dyskinesia. Its lead compound, SD-809, is a novel inhibitor of the vesicular monoamine transporter 2 (VMAT-2). This drug offers the potential for significant advantages over existing therapies including improved safety, reduced drug-drug interactions, and less frequent dosing. Auspex is also exploiting its deuterium chemistry approach to optimize drugs in several additional therapeutic areas. Included in the Auspex portfolio are SD-900, a JAK kinase inhibitor for the treatment of autoimmune diseases, and SD-560, for the treatment of fibrotic diseases, as well as other compounds.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/08/12 | $25,000,000 | Series D |
CMEA Capital Panorama Capital Sloan Biotech Fund Thomas, McNerney & Partners | undisclosed |
| 01/09/14 | $20,000,000 | Series E |
BioMed Ventures CMEA Capital Costa Verde Capital Deerfield Management Company, L.P. Panorama Capital Thomas, McNerney & Partners | undisclosed |
| 01/09/14 | $15,000,000 | Venture Debt |
Oxford Finance | undisclosed |
